HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

フルテキスト
JGastroenterol51_733.pdf252.65 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/66412

タイトル: Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
著者: Suda, Goki 著作を一覧する
Kudo, Mineo 著作を一覧する
Nagasaka, Atsushi 著作を一覧する
Furuya, Ken 著作を一覧する
Yamamoto, Yoshiya 著作を一覧する
Kobayashi, Tomoe 著作を一覧する
Shinada, Keisuke 著作を一覧する
Tateyama, Miki 著作を一覧する
Konno, Jun 著作を一覧する
Tsukuda, Yoko 著作を一覧する
Yamasaki, Kazushi 著作を一覧する
Kimura, Megumi 著作を一覧する
Umemura, Machiko 著作を一覧する
Izumi, Takaaki 著作を一覧する
Tsunematsu, Seiji 著作を一覧する
Sato, Fumiyuki 著作を一覧する
Terashita, Katsumi 著作を一覧する
Nakai, Masato 著作を一覧する
Horimoto, Hiromasa 著作を一覧する
Sho, Takuya 著作を一覧する
Natsuizaka, Mitsuteru 著作を一覧する
Morikawa, Kenichi 著作を一覧する
Ogawa, Koji 著作を一覧する
Sakamoto, Naoya 著作を一覧する
キーワード: HCV
Hemodialysis
Daclatasvir
Asunaprevir
発行日: 2016年 7月
出版者: Springer
誌名: Journal of gastroenterology
巻: 51
号: 7
開始ページ: 733
終了ページ: 740
出版社 DOI: 10.1007/s00535-016-1162-8
抄録: Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures. However, options of anti-HCV therapy in such patients are limited and unsatisfactory. In this study, we report effectiveness and safety of HCV-NS5A-inhibitor daclatasvir (DCV) and protease-inhibitor asunaprevir (ASV) combination therapy for hemodialysis patients with HCV infection. Methods: This study was registered at the UMIN Clinical Trials Registry as UMIN000016355. Thirty-four dialysis patients were treated with DCV/ASV combination therapy between January 2015 and November 2015. Of those, 21 patients who were followed more than 12 weeks after treatment ended were included. We evaluated the 12-week sustained virologic response (SVR12) and adverse events during treatment. Results: Of the 21 patients, four had compensated liver cirrhosis and three had resistance-associated variant of NS5A (NS5A RAVs)-Y93H at baseline. Overall, total of 95.5 % (20/21) of the patients achieved SVR12. Of note, all patients with cirrhosis or NS5A RAVs achieved SVR12. One relapser patient at 4 weeks post-treatment had NS3 D168E RAVs at baseline. A total of 20 patients (95.5 %) completed the 24-week therapy. One patient discontinued treatment at week 12 due to ALT elevations and achieved SVR12. Conclusions: DAV and ASV combination therapy for chronic hemodialysis patients with HCV infection was highly effective and well tolerated, even in elderly patients and patients with liver cirrhosis and NS5A-RAVs.
Rights: The final publication is available at Springer via http://dx.doi.org/10.1007/s00535-016-1162-8
資料タイプ: article (author version)
URI: http://hdl.handle.net/2115/66412
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 須田 剛生

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学